Bretta Russell-Schulz1, Jasmyne Kassam2, Michael Waine2, Erin L MacMillan1,3,4, Irene Vavasour1, Helen Cross2, Anthony Traboulsee2, Robert Carruthers2, and Shannon Kolind2,5,6
1Radiology, UBC MRI Research Centre, Vancouver, BC, Canada, 2Medicine, University of British Columbia, Vancouver, BC, Canada, 3Philips Healthcare Canada, Markham, ON, Canada, 4Simon Fraser University's ImageTech Lab, Surrey, BC, Canada, 5Physics & Astronomy, University of British Columbia, Vancouver, BC, Canada, 6Radiology, University of British Columbia, Vancouver, BC, Canada
1Radiology, UBC MRI Research Centre, Vancouver, BC, Canada, 2Medicine, University of British Columbia, Vancouver, BC, Canada, 3Philips Healthcare Canada, Markham, ON, Canada, 4Simon Fraser University's ImageTech Lab, Surrey, BC, Canada, 5Physics & Astronomy, University of British Columbia, Vancouver, BC, Canada, 6Radiology, University of British Columbia, Vancouver, BC, Canada
This study establishes pre-treatment baseline metabolite concentrations for a longitudinal clinical trial for RRMS and PPMS using 1H-MRS. The high MRS data quality and similar in FWHM across all participants creates a strong baseline for detecting change over time.
Figure 2a - Sample volume of interest (65x15x20mm3) in white matter region on MPRAGE ‘anatomical’ scan for healthy control.
b - Sample spectrum output from LCModel for each participant group with fit quality measures.
Figure 4 - Tissue content within VOI separated by subject
group and measures of spectrum fit quality (Full-Width-Half-Maximum, FWHM and
Signal-to-Noise Ratio, SNR); FWHM and SNR. Where WMf, GMf, CSFf and Lesionf,
are fraction of white matter, grey matter, cerebrospinal fluid and lesional
tissue, respectively.
